GH Research PLC GHRS 深 沪
已收盘 12-19 16:00:00 美东时间
12.96
+0.240
+1.89%
华盛通- 最 高15.86
- 今 开12.84
- 成交量 100.75万股
- 最 低 12.04
- 昨 收 12.72
- 总市值 6.74亿
- 52周最高 20.50
- 市盈率 静 --
- 换手率 1.94%
- 52周最低 6.95
- 委 比 -88.44%
- 总股本 5202.08万
- 历史最高 30.43
- 量 比 4.05
- 振 幅 30.03%
- 历史最低 1.10
- 每 手 1
- 风险率 2.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
GH Research PLC submitted its response to the FDA regarding the clinical hold of its GH001 IND in June, aiming to advance its novel inhaled mebufotenin treatment for treatment-resistant depression.
06-20 17:00
康乃德生物盘中异动 下午盘快速拉升7.00%
北京时间2025年02月04日03时33分，康乃德生物（CNTB.us）股票出现异动，股价快速拉升7.00%。截至发稿，该股报1.040美元/股，成交量2.2915万股，换手率0.04%，振幅7.20%。 最近的财报数据显示，该股实现营业收入24.12百万美元，净利润7.65百万美元，每股收益0.14美元，毛利23.64百万美元，市盈率-2.67倍。 机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。 康乃德生物股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Hcw Biologics Inc.、Invivyd, Inc.、Gh Re...
02-04 03:33
HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates GH Research (NASDAQ:GHRS) with a Buy and maintains $40 price target.
2024-09-06 02:36
JMP Securities Reiterates Market Outperform on GH Research, Maintains $39 Price Target
JMP Securities analyst Jason Butler reiterates GH Research (NASDAQ:GHRS) with a Market Outperform and maintains $39 price target.
2024-09-05 00:21
GH Research Names Velichka Valcheva as CEO
10:24 AM EDT, 09/03/2024 (MT Newswires) -- GH Research (GHRS) said Tuesday it has promoted Velichka Valcheva to the role of chief executive. Valcheva succeeds Theis Terwey, co-founder of GH Research, the company said. Valcheva joined GH Research in August 2023 was chief medical officer since Februar...
2024-09-03 22:24
GH Research Appoints Dr. Velichka 'Villy' Valcheva As New Chief Executive Officer
GH Research PLC a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka "Villy" Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Te...
2024-09-03 19:25
